Zevra Therapeutics
Mark Meier is a seasoned marketing professional with extensive experience in the pharmaceutical and biotech industries. Currently, Mark serves as Sr. Director of Marketing at Zevra Therapeutics, where the focus includes leading the launch of the first FDA-approved treatment for Niemann-Pick disease type C. Prior roles include Senior Vice President Commercial at Fennec Pharmaceuticals, where Mark successfully led the launch of a pediatric treatment, and Head of Sales at Orphazyme A/S, where a sales organization for rare diseases was established. Mark’s career also includes significant positions at Eli Lilly and Company, Horizon, Marathon Pharmaceuticals, Lundbeck, Galderma, and Stiefel Laboratories, contributing to product launches and marketing strategies across various therapeutic areas. Mark holds a BS in Marketing from Indiana University Indianapolis and completed an Executive Education program in Digital Marketing at Columbia Business School.
This person is not in any teams
This person is not in any offices
Zevra Therapeutics
1 followers
We are a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies. With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients. Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients’ lives.